Rebecca Burne

Education

Ph.D., biostatistics, McGill University, Montreal; M.Sc., statistics, University of KwaZulu Natal, South Africa; B.Sc., statistics and applied mathematics, University of KwaZulu Natal, South Africa

Summary of Experience

Dr. Burne is a biostatistician who specializes in health economics and outcomes research (HEOR), biostatistics, and epidemiology. Her experience includes retrospective analyses of various data sources such as medical insurance claims and electronic medical records, and the design of chart review studies. Dr. Burne has conducted research in multiple clinical areas, such as oncology, hematology, cardiology, and gastroenterology. Her research has been published in numerous peer-reviewed medical journals, including the New England Journal of Medicine, The Lancet, Advances in Therapy, and Statistical Methods in Medical Research. Prior to joining Analysis Group, Dr. Burne was a research assistant and course lecturer at McGill University.

Selected Publishing

• Treatment Discontinuation Patterns for Patients with Chronic Lymphocytic Leukemia in Real-World Settings: Results from a Multi-Center International Study

  Clinical Lymphoma, Myeloma & Leukemia, 2023
  2023

  Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR

  HEOR, Epidemiology & Market Access
• Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States

  Journal of Medical Economics, 2021
  2021

  Volk ML, Burne R, Guérin A, Shi S, Joseph GJ, Heimanson Z, Ahmad M

  HEOR, Epidemiology & Market Access
• Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors

  Journal of Medical Economics, 2021
  2021

  Burne R, Balu S, Guérin A, Bungay R, Sin R, Paul ML

  HEOR, Epidemiology & Market Access
• In-hospital Therapy for Heart Failure with Reduced Ejection Fraction in the United States

  Journal of the American College of Cardiology: Heart Failure, 2020
  2020

  Greene SJ, Triana TS, Ionescu-Ittu R, Burne RM, Guérin A, Borentain M, Kessler PD, Tugcu A, DeSouza MM, Felker GM, Chen L

  HEOR, Epidemiology & Market Access
• Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study

  Future Oncology. 2019 Feb;15(4):359-370
  2019

  Tarhini A, Ghate S, Ionescu-Ittu R, Shi S, Nakasato A, Ndife B, Laliberté F, Burne R, Duh MS

  HEOR, Epidemiology & Market Access
• Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review

  Melanoma Management, 2019
  2019

  Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, Guérin A, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS

  HEOR, Epidemiology & Market Access
• Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer

  Advances in Therapy. 2018 Sep;35(9):1356-1367
  2018

  Dalal AA, Gauthier G, Gagnon-Sanschagrin P, Burne R, Guérin A, Niravath P, Small T

  HEOR, Epidemiology & Market Access
• Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy

  Current Medical Research and Opinion. 2018 Dec;34(12):2169-2176
  2018

  Ghate SR, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS

  HEOR, Epidemiology & Market Access
• Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive

  Melanoma Research, October 9, 2018
  2018

  Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS

  HEOR, Epidemiology & Market Access
• Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma

  Melanoma Research. 2018 Dec;28(6):618-628
  2018

  Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberté F, Nakasato A, Burne R, Duh MS

  HEOR, Epidemiology & Market Access
• Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer

  Advances in Therapy. April 13, 2018
  2018

  Dalal AA, Gagnon-Sanschagrin P, Burne R, Guérin A, Gauthier G, Small T, Niravath P

  HEOR, Epidemiology & Market Access
• Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women

  Advances in Therapy. Mar 20 2018
  2018

  Gauthier G, Gagnon-Sanschagrin P, Guérin A, Burne R, Small T, Niravath P, Dalal AA

News

• December 1, 2023

  Analysis Group Consultants to Contribute 18 New Outcomes Research Presentations at 65th American Society of Hematology Annual Meeting and Exposition

  Health Care, HEOR, Epidemiology & Market Access